Gene Therapy with P14/tBID Induces Selective and Synergistic Apoptosis in Mutant Ras and Mutant P53 Cancer Cells In Vitro and In Vivo

Overview

Journal Biomedicines

Specialty Biomedical Engineering

Date 2023 Feb 25

PMID 36830797

Authors

Robert L Fine

Yuehua Mao

Dario Garcia-Carracedo

Gloria H Su

Wanglong Qiu

Uri Hochfeld

Gwen Nichols

Yong-Liang Li

Richard D Dinnen

Anthony Raffo

Paul W Brandt-Rauf

Affiliations

Soon will be listed here.

Abstract

Any gene therapy for cancer will be predicated upon its selectivity against cancer cells and non-toxicity to normal cells. Therefore, safeguards are needed to prevent its activation in normal cells. We designed a minimal p14 promoter with upstream Ap1 and E2F enhancer elements and a downstream MDR1 inhibitory element, TATA box, and a transcription initiation site (hereafter p14min). The modified p14min promoter was linked to bicistronic and truncated () genes, which led to synergistic apoptosis via the intrinsic and extrinsic pathways of apoptosis when expressed. The promoter was designed to be preferentially activated by mutant Ras and completely inhibited by wild-type p53 so that only cells with both mutant Ras and mutant p53 would activate the construct. In comparison to most p53 gene therapies, this construct has selective advantages: (1) p53-based gene therapies with a constitutive CMV promoter cannot differentiate between normal cells and cancer cells, and can be toxic to normal cells; (2) our construct does not induce p21 in contrast to other p53-based gene therapies, which can induce cell cycle arrest leading to increased chemotherapy resistance; (3) the modified construct (p14min-p14-tBID) demonstrates bidirectional control of its promoter, which is completely repressed by wild-type p53 and activated only in cells with both and mutations; and (4) a novel combination of genes (p14 and tBID) can synergistically induce potent intrinsic and extrinsic apoptosis in cancer cells.

References

Olive K, Jacobetz M, Davidson C, Gopinathan A, McIntyre D, Honess D . Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science. 2009; 324(5933):1457-61. PMC: 2998180. DOI: 10.1126/science.1171362. View

Takeda S, Nakao A, Miyoshi K, Takagi H . Gene therapy for pancreatic cancer. Semin Surg Oncol. 1998; 15(1):57-61. DOI: 10.1002/(sici)1098-2388(199807/08)15:1<57::aid-ssu10>3.0.co;2-0. View

Hingorani S, Wang L, Multani A, Combs C, Deramaudt T, Hruban R . Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice. Cancer Cell. 2005; 7(5):469-83. DOI: 10.1016/j.ccr.2005.04.023. View

Midgley C, Desterro J, Saville M, Howard S, Sparks A, Hay R . An N-terminal p14ARF peptide blocks Mdm2-dependent ubiquitination in vitro and can activate p53 in vivo. Oncogene. 2000; 19(19):2312-23. DOI: 10.1038/sj.onc.1203593. View

Moore P, Sipos B, Orlandini S, Sorio C, Real F, Lemoine N . Genetic profile of 22 pancreatic carcinoma cell lines. Analysis of K-ras, p53, p16 and DPC4/Smad4. Virchows Arch. 2002; 439(6):798-802. DOI: 10.1007/s004280100474. View

Palmero I, Pantoja C, Serrano M . p19ARF links the tumour suppressor p53 to Ras. Nature. 1998; 395(6698):125-6. DOI: 10.1038/25870. View

Olive K, Tuveson D, Ruhe Z, Yin B, Willis N, Bronson R . Mutant p53 gain of function in two mouse models of Li-Fraumeni syndrome. Cell. 2004; 119(6):847-60. DOI: 10.1016/j.cell.2004.11.004. View

Groth A, Weber J, Willumsen B, Sherr C, Roussel M . Oncogenic Ras induces p19ARF and growth arrest in mouse embryo fibroblasts lacking p21Cip1 and p27Kip1 without activating cyclin D-dependent kinases. J Biol Chem. 2000; 275(35):27473-80. DOI: 10.1074/jbc.M003417200. View

Schmitt C, McCurrach M, de Stanchina E, Wallace-Brodeur R, Lowe S . INK4a/ARF mutations accelerate lymphomagenesis and promote chemoresistance by disabling p53. Genes Dev. 1999; 13(20):2670-7. PMC: 317110. DOI: 10.1101/gad.13.20.2670. View

10.

Jacobetz M, Chan D, Neesse A, Bapiro T, Cook N, Frese K . Hyaluronan impairs vascular function and drug delivery in a mouse model of pancreatic cancer. Gut. 2012; 62(1):112-20. PMC: 3551211. DOI: 10.1136/gutjnl-2012-302529. View

11.

Dinnen R, Mao Y, Qiu W, Cassai N, Slavkovich V, Nichols G . Redirecting apoptosis to aponecrosis induces selective cytotoxicity to pancreatic cancer cells through increased ROS, decline in ATP levels, and VDAC. Mol Cancer Ther. 2013; 12(12):2792-803. PMC: 4318573. DOI: 10.1158/1535-7163.MCT-13-0234. View

12.

Lowe S, Sherr C . Tumor suppression by Ink4a-Arf: progress and puzzles. Curr Opin Genet Dev. 2003; 13(1):77-83. DOI: 10.1016/s0959-437x(02)00013-8. View

13.

Fine R, Mao Y, Dinnen R, Rosal R, Raffo A, Hochfeld U . C-Terminal p53 Palindromic Tetrapeptide Restores Full Apoptotic Function to Mutant p53 Cancer Cells In Vitro and In Vivo. Biomedicines. 2023; 11(1). PMC: 9855826. DOI: 10.3390/biomedicines11010137. View

14.

Kim M, Li X, Deng J, Zhang Y, Dai B, Allton K . Oncogenic Recruits an Expansive Transcriptional Network through Mutant p53 to Drive Pancreatic Cancer Metastasis. Cancer Discov. 2021; 11(8):2094-2111. PMC: 8338884. DOI: 10.1158/2159-8290.CD-20-1228. View

15.

Robertson K, Jones P . The human ARF cell cycle regulatory gene promoter is a CpG island which can be silenced by DNA methylation and down-regulated by wild-type p53. Mol Cell Biol. 1998; 18(11):6457-73. PMC: 109232. DOI: 10.1128/MCB.18.11.6457. View

16.

Lee C, Song I, Lee A, Kang J, Lee Y, Lee I . Enhancing the landscape of colorectal cancer using targeted deep sequencing. Sci Rep. 2021; 11(1):8154. PMC: 8046812. DOI: 10.1038/s41598-021-87486-3. View

17.

Provenzano P, Cuevas C, Chang A, Goel V, Von Hoff D, Hingorani S . Enzymatic targeting of the stroma ablates physical barriers to treatment of pancreatic ductal adenocarcinoma. Cancer Cell. 2012; 21(3):418-29. PMC: 3371414. DOI: 10.1016/j.ccr.2012.01.007. View

18.

Schneider G, Schmid R . Genetic alterations in pancreatic carcinoma. Mol Cancer. 2003; 2:15. PMC: 150381. DOI: 10.1186/1476-4598-2-15. View

19.

Sun C, Yamato T, Furukawa T, Ohnishi Y, Kijima H, Horii A . Characterization of the mutations of the K-ras, p53, p16, and SMAD4 genes in 15 human pancreatic cancer cell lines. Oncol Rep. 2000; 8(1):89-92. DOI: 10.3892/or.8.1.89. View

20.

Johnson R, Ince T, Scotto K . Transcriptional repression by p53 through direct binding to a novel DNA element. J Biol Chem. 2001; 276(29):27716-20. DOI: 10.1074/jbc.C100121200. View